|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
MarketWatch (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News